Sandra Gregorio-Sanchez

Pamplona, NC, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.

Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 05, 2025

A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer - The MONEO Study.

A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer - The MONEO Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 31, 2025

Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism.

Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism.

Journal: Oncoimmunology

Published: July 11, 2024

Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps.

Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 09, 2023

Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies.

Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies.

Journal: EMBO molecular medicine

Published: April 04, 2023

Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists.

Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists.

Journal: Molecular therapy. Nucleic acids

Published: January 11, 2023

Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma.

Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma.

Journal: Cell reports. Medicine

Published: September 16, 2022

Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity.

Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity.

Journal: Cancer immunology research

Published: May 07, 2022

Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL-8.

Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL-8.

Journal: The Journal of pathology

Published: March 07, 2021

CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation.

CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation.

Journal: Nature communications

Published: October 13, 2020

Showing 1-10 of 10

Last Updated: 09/26/2026